Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), filed a Form 4 on September 11, 2026, reporting transactions in the company's common stock dated September 10, 2026.

Key Highlights

  • Reporting person: Andrew D. Dickinson, identified in the filing as Chief Financial Officer of Gilead Sciences, Inc.
  • RSU conversion: 2,797 restricted stock units were converted to common stock on September 10, 2026, under transaction code M.
  • Shares withheld: 1,347 shares of common stock were disposed of on September 10, 2026, under transaction code F, at a price of $144.81 per share.
  • Resulting direct ownership: 167,096 shares of common stock held directly following the reported transactions.
  • Remaining RSUs: 25,054 restricted stock units remain directly held following the reported transactions.
  • RSU vesting schedule: According to the filing, RSUs vest over four years, with 25% vesting on the first anniversary of the grant date and the balance vesting 6.25% quarterly thereafter until fully vested.

Gilead Sciences CFO Dickinson: RSU Settlement and Tax-Related Share Disposal

According to the filing, Dickinson acquired 2,797 shares of Gilead Sciences common stock on September 10, 2026, through the settlement of restricted stock units, recorded under transaction code M. Each restricted stock unit, as described in the filing's footnotes, "represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock." Following this acquisition, his directly held share count stood at 168,443 shares.

The filing also reports a same-day disposal of 1,347 shares under transaction code F at $144.81 per share, which reduced his directly held position to 167,096 shares. Transaction code F in SEC Form 4 filings denotes shares withheld by the issuer to satisfy a tax obligation upon vesting. The filing was signed by Amy Kim by Power of Attorney for Andrew D. Dickinson and submitted on September 11, 2026.

Gilead Sciences, Inc. is a biopharmaceutical company. The RSUs involved in the reported transactions carry a four-year vesting schedule, as disclosed in the filing's explanation of responses. Following the transactions, 25,054 restricted stock units remain directly beneficially owned by Dickinson, according to the filing's Table II. The filing notes this was made by one reporting person and was not designated as an amendment to a prior filing.

What Was Disclosed

The filing reported a September 10, 2026 settlement of 2,797 restricted stock units into common stock and a same-day disposal of 1,347 shares at $144.81 each, leaving Gilead Sciences CFO Andrew D. Dickinson with direct ownership of 167,096 common shares and 25,054 remaining RSUs.